hoffmann
et
al
cell
identifi
receptor
latter
show
entri
mechan
depend
cellular
serin
proteas
result
may
explain
proinflammatori
cytokin
releas
via
associ
angiotestin
ii
pathway
possibl
therapeut
target
via
axi
past
two
decad
sever
acut
respiratori
syndrom
coronaviru
sarscov
middl
east
respiratori
syndrom
coronaviru
merscov
transmit
anim
human
caus
sever
respiratori
diseas
sar
mer
endem
area
decemb
anoth
coronaviru
discov
patient
infecti
respiratori
diseas
wuhan
hubei
provinc
china
abil
humantohuman
transmiss
diseas
term
coronaviru
diseas
spread
rapidli
world
result
pandem
induc
pathogen
sarscoronaviru
associ
case
death
april
map
john
hopkin
univers
medicin
major
phenotyp
sever
acut
respiratori
distress
syndrom
ard
like
diseas
caus
sarscov
merscov
de
wit
et
al
huang
et
al
lu
et
al
zhou
et
al
report
genom
character
epidemiolog
lu
et
al
zhou
et
al
genom
sequenc
similar
distinct
two
coronavirus
sequenc
ident
sarscov
merscov
interestingli
ident
wholegenom
level
two
bat
coronavirus
collect
eastern
china
protein
sequenc
analysi
show
seven
conserv
nonstructur
domain
like
sarscov
suggest
two
coronavirus
relat
furthermor
similar
receptorbind
domain
structur
sarscov
despit
amino
acid
variat
key
residu
thu
possibl
use
cell
entri
receptorangiotensin
convert
enzym
ii
sarscov
li
et
al
consid
high
mortal
rate
world
develop
effect
therapeut
urgent
issu
requir
identif
qualiti
target
regard
two
paper
identifi
cell
entri
receptor
hoffmann
et
al
zhou
et
al
addit
hoffman
colleagu
show
receptormedi
viru
entri
depend
serin
proteas
transmembran
serin
proteas
note
clinic
approv
inhibitor
prevent
cell
entri
alveola
type
cell
highli
express
steadi
state
cell
might
primari
entri
cell
lung
zhou
et
al
perform
viru
infect
studi
use
hela
cell
express
protein
origin
human
chines
horsesho
bat
civet
pig
mice
show
enter
cell
express
protein
except
mous
could
enter
cell
lack
suggest
viru
util
entri
receptor
addit
enter
cell
lack
express
either
dipeptidyl
peptidas
aminopeptidas
n
apn
entri
receptor
merscov
respect
known
cell
entri
coronaviru
requir
bind
region
viru
spike
protein
cell
surfac
receptor
follow
fusion
viral
cellular
membran
mediat
subunit
protein
process
requir
protein
prime
host
cell
proteas
entail
protein
cleavag
boundari
protein
within
subunit
analyz
cellular
factor
use
cell
entri
provid
insight
viral
transmiss
reveal
effect
therapeut
target
hoffmann
et
al
perform
detail
analysi
cell
entri
mechan
demonstr
use
entri
endosom
cystein
proteas
cathepsin
b
l
catbl
protein
prime
also
show
protein
effici
cleav
site
cell
furthermor
util
replicationdefect
vesicular
stomat
viru
vsv
particl
bear
either
sarscov
protein
sarss
show
either
protein
enter
cell
ident
spectrum
cell
line
variou
anim
speci
consist
amino
acid
residu
essenti
bind
sarss
conserv
lu
et
al
zhou
et
al
fact
sarss
enter
cell
cell
express
human
bat
forc
express
human
human
apn
furthermor
antibodi
human
block
sarssand
entri
human
cell
line
result
indic
like
sarss
use
cellular
entri
hoffmann
et
al
investig
proteas
depend
entri
entri
cell
express
inhibit
ammonium
chlorid
inhibitor
catbl
entri
cell
less
effici
inhibit
clinic
proven
inhibitor
camostat
mesyl
partial
inhibit
entri
cell
camostat
mesyl
togeth
inhibitor
catbl
complet
inhibit
entri
suggest
catbl
involv
entri
howev
forc
express
rescu
entri
catblsuppress
cell
suggest
entri
induc
cell
express
regardless
catbl
express
entri
lung
cell
also
inhibit
camostat
mesyl
find
show
cell
entri
depend
surfac
molecul
togeth
zhou
et
al
hoffmann
et
al
show
use
cell
entri
receptor
sarscov
importantli
result
suggest
therapeut
target
one
bind
protein
serin
proteas
activ
protein
prime
therapeut
target
may
act
initi
phase
infect
dominantli
latter
phase
diseas
extrem
power
chronic
inflamm
induc
latter
phase
main
caus
ardsmedi
death
de
wit
et
al
consist
ard
lethal
syndrom
caus
pneumonia
sepsi
aspir
due
cytokin
storm
immun
cell
nonimmun
cell
releas
larg
amount
proinflammatori
cytokin
caus
damag
host
hyperactiv
nfkb
pathway
involv
phenotyp
one
major
pathway
nfkb
activ
coronaviru
infect
pathway
pattern
recognit
receptor
prr
lead
induct
varieti
proinflammatori
cytokin
includ
tumor
necrosi
factor
alpha
tnfa
chemokin
de
wit
et
al
membran
protein
inactiv
angiotensin
angii
importantli
endocytos
togeth
sarscov
result
reduct
cell
follow
increas
serum
angii
also
downregul
lunginjuri
model
recombin
suppress
ard
develop
sever
lung
inflamm
might
induc
dysregul
reninangiotensin
pathway
follow
ard
develop
infect
inde
sarscovinduc
ard
anim
model
prevent
inhibitor
angiotensin
receptor
type
angii
act
vasoconstrictor
also
proinflammatori
cytokin
via
eguchi
et
al
axi
also
activ
nfkb
disintegrin
metalloproteas
gener
matur
form
epiderm
growth
factor
receptor
egfr
ligand
tnfa
two
nfkb
stimul
eguchi
et
al
induct
also
process
membran
form
solubl
form
follow
activ
via
complex
varieti
nonimmun
cell
includ
fibroblast
endotheli
cell
epitheli
cell
murakami
et
al
requir
full
activ
nfkb
pathway
main
stimul
vivo
especi
inflamm
although
nine
member
famili
cytokin
activ
least
vitro
murakami
et
al
therefor
infect
respiratori
system
activ
nfkb
turn
activ
amplifi
amp
mechan
hyperactiv
nfkb
lead
multipl
use
angiotensin
convert
enzym
ii
transmembran
serin
proteas
cell
entri
receptor
follow
cytokinerel
syndrom
ard
induc
hyperactiv
transcript
factor
nfkb
like
nonimmun
cell
includ
lung
epitheli
cell
molecul
cell
surfac
occupi
angiotensin
angii
increas
serum
due
reduct
degrad
activ
nfkb
via
pattern
recognit
receptor
ppr
accumul
angii
induc
inflammatori
cytokin
includ
tnfa
via
disintegrin
metalloproteas
follow
activ
amplifi
amp
describ
enhanc
nfkb
activ
machineri
via
coactiv
nfkb
transcript
factor
molecul
underlin
indic
possibl
therapeut
target
cytokin
releas
syndrom
cr
inflammatori
autoimmun
diseas
murakami
et
al
amp
induc
variou
proinflammatori
cytokin
chemokin
includ
recruit
lymphoid
cell
myeloid
cell
activ
cell
macrophag
lesion
strengthen
amp
posit
feedback
loop
figur
importantli
major
function
marker
cellular
senesc
agedepend
enhanc
amp
might
correspond
agedepend
increas
mortal
inde
ard
seen
infect
cytokin
releas
syndrom
cr
disord
induc
cytokin
storm
lethal
side
effect
cr
found
chimer
antigen
receptor
car
cell
therapi
leukemia
lymphoma
also
associ
elev
inflammatori
cytokin
neelapu
et
al
possibl
enhanc
proinflammatori
cytokin
induc
amp
consid
antibodi
tocilizumab
effect
treatment
cr
cart
cell
therapi
neelapu
et
al
research
might
want
consid
drug
similar
mechan
action
cr
taken
togeth
demonstr
receptor
cellular
entri
provid
key
target
therapeut
develop
initi
phase
infect
later
phase
potenti
dysregul
pathway
downstream
could
lead
cytokin
releas
syndrom
observ
patient
may
requir
target
cytokin
pathway
particularli
axi
